Amaç: İnterlökin-6’nın (IL-6) periodontal hastalık patogenezi ve periodontal doku yıkımındaki rolü geniş çapta ele alınmıştır. Çalışmanın amacı, evre IV periodontitis hastalarının tükürüklerindeki IL-6 seviyelerini değerlendirmektir. Gereç ve Yöntemler: Araştırmaya evre IV periodontitis teşhisi konulan 28 hasta ile 22 hastadan oluşan kontrol grubu dahil edildi. Hastaların tümü sistemik olarak sağlıklıydı. Tükürük örnekleri toplandı ve sondalama derinliği (SD), klinik ataşman seviyesi (KAS), papil kanama indeksi (PKİ), sondalamada kanama yüzdesi (SK %), plak indeksi (Pİ) ve diştaşı indeksini (Dİ) içeren klinik periodontal ölçümler kaydedildi. Her bir hastanın uyarılmamış tükürükleri, tükürük toplayıcı ile toplandı ve örneklerdeki IL-6 seviyesi enzim bağlı immünosorbent testi ile analiz edildi. Bulgular: Evre IV periodontitis hastalarının ortalama IL-6 değeri 22,18±5,96 pg/mL idi. Kontrol grubunun ortalama IL-6 değeri ise 2,23±2,17 pg/mL idi. Periodontitis Objective: The role of interleukin-6 (IL-6) in the pathogenesis of periodontal disease and tissue destruction at the periodontal site has been widely reported. This study aimed to evaluate the salivary IL-6 levels in patients with stage IV periodontitis. Materials and Methods: The study included 28 patients who were diagnosed with periodontitis stage IV and the control group of 22 periodontally healthy patients. All the patients were systemically healthy. Saliva samples were collected, and clinical periodontal measurements, including probing depth (PD), clinical attachment level (CAL), papilla bleeding index (PBI), the percentage of sites with bleeding on probing (BOP) %, plaque index (PI) and calculus index (CI), were recorded. The unstimulated saliva of each patient was collected by a saliva collector, and all samples were analysed using the enzyme-linked immunosorbent assay method for the detection of IL-6. Results: The mean value of salivary IL-6 in patients with periodontitis stage IV was 22.18±5.96 pg/mL. In the control group, the average measured value of IL-6 was 2.23±2.17 pg/mL. The periodontitis group had a significantly higher salivary IL-6 levels than the control group. A strong positive correlation was observed between the salivary IL-6 and clinical periodontal parameters (PD, CAL, PBI, BOP %, PI and CI) in patients with periodontitis stage IV (p<0.0001). Conclusion: We demonstrated a statistically significant relationship between periodontal parameters and salivary IL-6 in patients with periodontitis stage IV. New studies are needed to accurately establish salivary IL-6 potential as a biomarker for periodontal disease monitoring, including all stages and grades of periodontitis.

Introduction: C-reactive Protein (CRP) as an inflammatory biomarker can be easily determined in saliva, but the values of salivary CRP in periodontitis are not well-studied. The aim of this study was to analyze and determine the values of salivary CRP in non-smokers with periodontitis stage 3 or 4 before and after supragingival and subgingival full-mouth periodontal therapy.Methods: Standard periodontal parameters and saliva samples were collected in 12 non-smoking patients. Patients in the test group (n = 6) underwent supragingival and subgingival full-mouth periodontal therapy, and the control group (n = 6) received only supragingival full-mouth therapy. Both groups received the same oral hygiene instructions in addition to therapy. After 3 months, re-registration of periodontal parameters and re-sampling of saliva for analysis of salivary CRP were done for both groups.Results: Statistical analysis revealed large differences in the values of clinical periodontal parameters and CRP levels in the test group after therapy. Values of salivary CRP in the test and control groups were lower 3 months the therapy; however, the results were not statistically significant. The correlation of clinical periodontal parameters and salivary CRP varied in both groups.Conclusion: Our pilot study reveals decreased concentrations of salivary C-reactive protein in non-smoking patients following non-surgical periodontal therapy. Further studies are needed to prove the reliability of salivary CRP as a biomarker for periodontitis.

Summary Background/Aim: This study aimed to evaluate the effects of Lactobacillus reuteri lozenges as an adjunctive therapeutic agent in combination with scaling and root planing in a randomized, clinical trial of volunteers with periodontitis stage IV. Material and Methods: The study included 40 patients diagnosed with periodontitis divided into 2 groups of 20 patients by random sample method. The first group of patients used Lactobacillus reuteri lozenges after nonsurgical periodontal therapy for a period of 40 days while the second group of patients was treated with non-surgical periodontal therapy without lozenges. Periodontal clinical parameters were registered for all patients before treatment and after 40 days. Samples of saliva from patients before and 40 days after treatment were analyzed by the PCR method for pathogens Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, and Prevotella intermedia. Assessments were made on day 0 before treatment for patients of both groups and after 40 days. Results: Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis show a statistically significant difference between the two study groups. Results were not statistically significant for Prevotella intermedia (P= 0.5598). Conclusions: The present study confirms the positive effects of L. reuteri lozenges after non-surgical periodontal therapy and the maintenance phase of periodontal treatment. Considering the beneficial effects of probiotics, L.reuteri could serve as a useful adjunct or maybe even as an alternative to periodontal treatment when scaling and root planing might be contraindicated or has to be postponed.